UTRN on chromosome 6q24 is mutated in multiple tumors

被引:37
作者
Li, Y.
Huang, J.
Zhao, Y-L
He, J.
Wang, W.
Davies, K. E.
Nose, V.
Xiao, S.
机构
[1] Harbin Inst Technol, Harbin, Peoples R China
[2] Brigham & Womens Hosp, Harvard Med Sch, Dept Pathol, Boston, MA USA
[3] Cornell Univ, Microarray Core Facility, Ithaca, NY USA
[4] Univ Oxford, Dept Biochem, Oxford OX1 2JD, England
关键词
tumor suppressor; UTRN; functional screening;
D O I
10.1038/sj.onc.1210432
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Though deletion of the long arm of chromosome 6 is one of the most common aberrations in tumors, its targeted gene(s) has not been convincingly identified. Using a functional screening approach, we found that UTRN ( which encodes utrophin, a dystrophin-related protein) at 6q24, when expressed in an antisense orientation, induced cellular transformation, consistent with a tumor suppressor role. Northern blot analysis, semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), and gene expression arrays all showed that UTRN expression was downregulated in primary tumors compared with matched normal tissues. Several UTRN neighbor genes were not affected in some tumors with UTRN downregulation, suggesting that UTRN was specifically targeted. RT-PCR, coupled with an in vitro transcription and translation assay, revealed inactivation mutations in 21/62 breast cancers, 4/20 neuroblastomas and 4/15 malignant melanomas. Most of the mutations were deletions involving one or more exons that led to the truncation of utrophin. Splicing errors were found in two cases, and nonsense mutation in one case. Overexpression of a wild-type UTRN in breast cancer cells inhibited tumor cell growth in vitro and reduced their tumor potential in nude mice. Our studies suggest that UTRN is a candidate tumor suppressor gene.
引用
收藏
页码:6220 / 6228
页数:9
相关论文
共 38 条
[1]  
Abe T, 1999, GENE CHROMOSOME CANC, V25, P60, DOI 10.1002/(SICI)1098-2264(199905)25:1<60::AID-GCC9>3.0.CO
[2]  
2-Y
[3]   Loss of heterozygosity on chromosome arms 3p and 6q in microdissected adenocarcinomas of the uterine cervix and adenocarcinoma in situ [J].
Acevedo, CM ;
Henríquez, M ;
Emmert-Buck, MR ;
Chuaqui, RF .
CANCER, 2002, 94 (03) :793-802
[4]   Clonal chromosome changes including a del(6q) in a possible early lymphoma [J].
Atkin, NB ;
Jackson, Z .
CANCER GENETICS AND CYTOGENETICS, 1996, 92 (01) :87-89
[5]   Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors [J].
Barghorn, A ;
Speel, EJM ;
Farspour, B ;
Saremaslani, P ;
Schmid, S ;
Perren, A ;
Roth, J ;
Heitz, PU ;
Komminoth, P .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (06) :1903-1911
[6]   The future of antisense therapy: combination with anticancer treatments [J].
Biroccio, A ;
Leonetti, C ;
Zupi, G .
ONCOGENE, 2003, 22 (42) :6579-6588
[7]   G-UTROPHIN, THE AUTOSOMAL HOMOLOG OF DYSTROPHIN DP116, IS EXPRESSED IN SENSORY GANGLIA AND BRAIN [J].
BLAKE, DJ ;
SCHOFIELD, JN ;
ZUELLIG, RA ;
GORECKI, DC ;
PHELPS, SR ;
BARNARD, EA ;
EDWARDS, YH ;
DAVIES, KE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (09) :3697-3701
[8]  
Brault E, 2001, J CELL SCI, V114, P1901
[9]   Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas [J].
Chappell, SA ;
Walsh, T ;
Walker, RA ;
Shaw, JA .
BRITISH JOURNAL OF CANCER, 1997, 75 (09) :1324-1329
[10]   Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy [J].
Deconinck, AE ;
Rafael, JA ;
Skinner, JA ;
Brown, SC ;
Potter, AC ;
Metzinger, L ;
Watt, DJ ;
Dickson, JG ;
Tinsley, JM ;
Davies, KE .
CELL, 1997, 90 (04) :717-727